Display options
Cite
DeTolla L, Sanchez R, Khan E, et al. Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice. J Vet Med. 2014;2014:365673doi: 10.1155/2014/365673.
DeTolla, L., Sanchez, R., Khan, E., Tyler, B., & Guarnieri, M. (2014). Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice. Journal of veterinary medicine, 2014365673. https://doi.org/10.1155/2014/365673
DeTolla, L, et al. "Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice." Journal of veterinary medicine vol. 2014 (2014): 365673. doi: https://doi.org/10.1155/2014/365673
DeTolla L, Sanchez R, Khan E, Tyler B, Guarnieri M. Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice. J Vet Med. 2014;2014:365673. doi: 10.1155/2014/365673. Epub 2014 Nov 27. PMID: 26464927; PMCID: PMC4590835.
Copy Download .nbib Format: NLM
Share it on

J Vet Med. 2014;2014:365673. doi: 10.1155/2014/365673. Epub 2014 Nov 27.

Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice.

Journal of veterinary medicine

L DeTolla, R Sanchez, E Khan, B Tyler, M Guarnieri

Affiliations

  1. Departments of Pathology, Medicine, Epidemiology and Public Health and the Program of Comparative Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA.
  2. Program of Comparative Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA.
  3. Johns Hopkins School of Medicine Department of Neurological Surgery, 1550 Orleans Street CRB-264, Baltimore, MD 21231, USA.

PMID: 26464927 PMCID: PMC4590835 DOI: 10.1155/2014/365673

Abstract

Subcutaneous drug implants are convenient systems for the long-term delivery of drugs in animals. Lipid carriers are logical tools because they generally allow for higher doses and low toxicity. The present study used an US Food and Drug Administration Target Animal Safety test system to evaluate the safety of a subcutaneous implant of a cholesterol-triglyceride-buprenorphine powder in 120 BALB/c mice. Mice were evaluated in 4- and 12-day trials with 1- and 5-fold doses of the intended 3 mg/kg dose of drug. One male mouse treated with three 3 mg/kg doses and surgery on days 0, 4, and 8 died on day 9. The cause of death was not determined. In the surviving 119 mice there was no evidence of skin reaction at the site of the implant. Compared to control animals treated with saline, weight measurements, clinical pathology, histopathology, and clinical observations were unremarkable. These results demonstrate that the lipid carrier is substantially safe. Cholesterol-triglyceride-drug powders may provide a valuable research tool for studies of analgesic and inflammatory drug implants in veterinary medicine.

References

  1. PLoS One. 2012;7(4):e35656 - PubMed
  2. Lab Anim. 2010 Jan;44(1):54-8 - PubMed
  3. Comp Med. 2004 Oct;54(5):558-63 - PubMed
  4. Lab Anim. 2010 Jan;44(1):59-65 - PubMed
  5. Lab Anim (NY). 2012 Nov;41(11):337-43 - PubMed
  6. Lab Anim (NY). 2010 Aug;39(8):236-40 - PubMed
  7. J Am Assoc Lab Anim Sci. 2012 Jan;51(1):42-9 - PubMed
  8. Pharmacol Biochem Behav. 1983 Mar;18(3):471-4 - PubMed
  9. Drug Deliv Transl Res. 2012 Aug;2(4):238-53 - PubMed
  10. Anesth Analg. 2001 Oct;93(4):928-33 - PubMed
  11. Lab Anim. 2002 Jul;36(3):322-43 - PubMed
  12. Comp Med. 2006 Dec;56(6):487-92 - PubMed
  13. Acta Neurochir (Wien). 2010 Nov;152(11):1923-31 - PubMed
  14. J Pharm Pharmacol. 2006 Mar;58(3):295-302 - PubMed
  15. J Biomed Mater Res A. 2005 Oct 1;75(1):185-91 - PubMed
  16. Lab Anim. 2009 Apr;43(2):149-54 - PubMed
  17. Pharm Res. 2008 May;25(5):1052-62 - PubMed
  18. J Am Assoc Lab Anim Sci. 2011 Jul;50(4):507-12 - PubMed
  19. Comp Med. 2006 Apr;56(2):114-8 - PubMed
  20. J Am Assoc Lab Anim Sci. 2011 Mar;50(2):198-204 - PubMed
  21. Addiction. 2006 Mar;101(3):420-32 - PubMed
  22. J Addict Med. 2007 Jun;1(2):68-72 - PubMed
  23. J Pharm Pharmacol. 1978 May;30(5):325-6 - PubMed
  24. PLoS One. 2013 Apr 10;8(4):e60537 - PubMed
  25. Anesth Analg. 1994 Oct;79(4):706-9 - PubMed
  26. Lab Anim Sci. 1997 Jun;47(3):300-3 - PubMed
  27. Res Vet Sci. 2000 Dec;69(3):283-8 - PubMed
  28. Contemp Top Lab Anim Sci. 2003 Jan;42(1):28-34 - PubMed
  29. Lab Anim. 2012 Oct;46(4):287-92 - PubMed
  30. J Pharm Bioallied Sci. 2014 Jan;6(1):43-7 - PubMed
  31. Vet J. 2011 Mar;187(3):335-41 - PubMed
  32. Comp Med. 2004 Jun;54(3):293-300 - PubMed
  33. J Pharm Bioallied Sci. 2014 Jan;6(1):38-42 - PubMed
  34. Vet J. 2011 Feb;187(2):251-4 - PubMed
  35. Lab Anim. 2001 Jul;35(3):213-22 - PubMed
  36. Br J Pharmacol. 1977 Aug;60(4):547-54 - PubMed
  37. J Am Assoc Lab Anim Sci. 2010 Sep;49(5):610-6 - PubMed
  38. J Am Assoc Lab Anim Sci. 2012 Nov;51(6):815-9 - PubMed
  39. Contemp Top Lab Anim Sci. 2000 Mar;39(2):8-13 - PubMed

Publication Types